CL2025002304A1 - Compuestos de carbamoilpiridona tricíclicos en puente y usos de estos - Google Patents

Compuestos de carbamoilpiridona tricíclicos en puente y usos de estos

Info

Publication number
CL2025002304A1
CL2025002304A1 CL2025002304A CL2025002304A CL2025002304A1 CL 2025002304 A1 CL2025002304 A1 CL 2025002304A1 CL 2025002304 A CL2025002304 A CL 2025002304A CL 2025002304 A CL2025002304 A CL 2025002304A CL 2025002304 A1 CL2025002304 A1 CL 2025002304A1
Authority
CL
Chile
Prior art keywords
compounds
tricyclic
bridging
carbamoylpyridone compounds
carbamoylpyridone
Prior art date
Application number
CL2025002304A
Other languages
English (en)
Inventor
Chu Hang
Z Gonzalez Buenrostro Ana
Han Xiaochun
E Hurtley Anna
Jiang Lan
Li Jiayao
M Schwarzwalder Gregg
M Shivakumar Devleena
J Von Bargen Matthew
Wu Qiaoyin
Yang Hong
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CL2025002304A1 publication Critical patent/CL2025002304A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente descripción se relaciona generalmente con compuestos de la Fórmula I: También se describen composiciones farmacéuticas que comprenden dichos compuestos y métodos para elaborar dichos compuestos. Los compuestos de la descripción son útiles para tratar o prevenir la infección por el virus de inmunodeficiencia humana (VIH)
CL2025002304A 2022-04-06 2025-08-01 Compuestos de carbamoilpiridona tricíclicos en puente y usos de estos CL2025002304A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263328061P 2022-04-06 2022-04-06
US202263476873P 2022-12-22 2022-12-22

Publications (1)

Publication Number Publication Date
CL2025002304A1 true CL2025002304A1 (es) 2025-11-21

Family

ID=86330110

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2024002988A CL2024002988A1 (es) 2022-04-06 2024-10-03 Compuestos de carbamoilpiridona tricíclicos en puente y usos de estos
CL2025002302A CL2025002302A1 (es) 2022-04-06 2025-08-01 Compuestos de carbamoilpiridona tricíclicos en puente y usos de estos
CL2025002304A CL2025002304A1 (es) 2022-04-06 2025-08-01 Compuestos de carbamoilpiridona tricíclicos en puente y usos de estos

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2024002988A CL2024002988A1 (es) 2022-04-06 2024-10-03 Compuestos de carbamoilpiridona tricíclicos en puente y usos de estos
CL2025002302A CL2025002302A1 (es) 2022-04-06 2025-08-01 Compuestos de carbamoilpiridona tricíclicos en puente y usos de estos

Country Status (26)

Country Link
US (3) US12054496B2 (es)
EP (3) EP4438123A3 (es)
JP (3) JP7668428B2 (es)
KR (2) KR20250002321A (es)
CN (2) CN118922419B (es)
AU (3) AU2023249631B2 (es)
CA (1) CA3245817A1 (es)
CL (3) CL2024002988A1 (es)
CO (1) CO2024013492A2 (es)
CR (1) CR20240405A (es)
DK (2) DK4305034T3 (es)
DO (3) DOP2024000195A (es)
ES (2) ES2988416T3 (es)
FI (2) FI4305034T3 (es)
HR (2) HRP20241051T1 (es)
HU (2) HUE067768T2 (es)
IL (1) IL315684A (es)
LT (2) LT4305034T (es)
MX (1) MX2024011695A (es)
PE (3) PE20252269A1 (es)
PL (2) PL4305034T3 (es)
PT (2) PT4305034T (es)
SI (2) SI4305034T1 (es)
TW (3) TWI856796B (es)
WO (1) WO2023196875A1 (es)
ZA (2) ZA202406990B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016069660A1 (en) 2014-10-27 2016-05-06 Intuitive Surgical Operations, Inc. System and method for monitoring control points during reactive motion
EP3212151B1 (en) 2014-10-27 2020-07-29 Intuitive Surgical Operations, Inc. System for integrated surgical table motion
IL286328B1 (en) 2019-03-22 2026-04-01 Gilead Sciences Inc Tricyclic bridging compounds of carbamoylpyridone and their pharmaceutical use
CR20220418A (es) 2020-02-24 2022-10-10 Gilead Sciences Inc Compuestos tetracíclicos para el tratamiento de infecciones por vih
CA3192145A1 (en) 2020-09-30 2022-04-07 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
JP7591155B2 (ja) 2021-01-19 2024-11-27 ギリアード サイエンシーズ， インコーポレイテッド 置換ピリドトリアジン化合物及びその使用
TW202515549A (zh) * 2023-10-11 2025-04-16 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
AU2024360779A1 (en) * 2023-10-11 2026-04-16 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
CN122055369A (zh) * 2023-10-11 2026-05-15 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其用途
TW202525289A (zh) * 2023-12-22 2025-07-01 美商基利科學股份有限公司 用於製備治療性化合物之方法及中間物
WO2026076265A1 (en) * 2024-10-03 2026-04-09 Gilead Sciences, Inc. Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
CN1291994C (zh) 2000-07-21 2006-12-27 吉里德科学公司 核苷酸膦酸酯类似物前药及其筛选和制备方法
PL1628685T3 (pl) 2003-04-25 2011-05-31 Gilead Sciences Inc Przeciwwirusowe analogi fosfonianowe
EP1778251B1 (en) 2004-07-27 2011-04-13 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
ATE516026T1 (de) 2005-02-21 2011-07-15 Shionogi & Co Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung
AU2006228278C1 (en) 2005-03-31 2011-06-23 Msd Italia S.R.L. HIV integrase inhibitors
PT1874117E (pt) 2005-04-28 2013-10-17 Shionogi & Co Derivado policíclico de carbamoílpiridona possuindo actividade inibidora de hiv-integrasse
JP2006342115A (ja) 2005-06-10 2006-12-21 Shionogi & Co Ltd Ｈｉｖインテグラーゼ阻害活性を有する多環性化合物
EP1910363A4 (en) 2005-08-04 2010-05-26 Glaxosmithkline Llc INHIBITORS OF HIV INTEGRASE
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TWI404537B (zh) 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
AU2006306355A1 (en) 2005-10-27 2007-05-03 Merck & Co., Inc. HIV integrase inhibitors
AU2006307101A1 (en) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
TW200811153A (en) 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
SI2049506T2 (sl) 2006-07-07 2024-07-31 Gilead Sciences, Inc. Modulatorji farmakokinetičnih lastnosti terapevtikov
CA2657287A1 (en) 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
AU2007313293A1 (en) 2006-10-18 2008-04-24 Merck & Co., Inc. HIV integrase inhibitors
SI2170888T1 (sl) 2007-06-29 2015-10-30 Gilead Sciences, Inc. Purinski derivati in njihova uporaba kot modulatorjev receptorja tipa toll-7
WO2009062285A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
CA2710987A1 (en) 2008-01-08 2009-07-16 Merck Sharp & Dohme Corp. Process for preparing n-substituted hydroxypyrimidinone carboxamides
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
CN104387382A (zh) 2008-03-24 2015-03-04 梅迪维新技术公司 吡啶并[3,4-b]吲哚和应用方法
HRP20130048T1 (hr) 2008-04-23 2013-02-28 Gilead Sciences, Inc. Karba-nukleozidni analozi za antivirusnu terapiju
WO2009154870A1 (en) 2008-05-05 2009-12-23 Merck & Co., Inc. Hiv integrase inhibitors
US8426405B2 (en) 2008-07-02 2013-04-23 Avexa Limited Thiazopyrimidinones and uses thereof
WO2010011819A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011818A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
SI2320908T1 (sl) 2008-07-25 2014-05-30 Viiv Healthcare Company Predzdravila dolutegravirja
CN103951643B (zh) 2008-07-25 2015-12-09 盐野义制药株式会社 用作hiv整合酶抑制剂的化合物
JP5551697B2 (ja) 2008-07-25 2014-07-16 ビーブ・ヘルスケア・カンパニー 化合物
WO2010011815A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
JP5600104B2 (ja) 2008-08-01 2014-10-01 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッド Ｔｏｌｌ様受容体アゴニスト処方物およびその使用
AU2009302663B2 (en) 2008-10-06 2012-11-08 Merck Sharp & Dohme Corp. HIV integrase inhibitors
AU2009333559B2 (en) 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
KR101733625B1 (ko) 2008-12-11 2017-05-10 시오노기세야쿠 가부시키가이샤 카르바모일피리돈 ｈｉｖ 인테그라제 억제제 및 중간체의 합성
EP2391212A4 (en) 2009-01-28 2012-08-08 BROKEN COMPOUNDS AS HIV INTEGRASE INHIBITORS
US8673307B1 (en) 2009-03-09 2014-03-18 The Rockefeller University HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
DK2444400T3 (en) 2009-06-15 2018-06-18 Shionogi & Co SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE
WO2011011483A1 (en) 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
RU2580320C2 (ru) 2009-08-18 2016-04-10 Вентиркс Фармасьютикалз, Инк. Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
PL2467377T3 (pl) 2009-08-18 2017-10-31 Ventirx Pharmaceuticals Inc Podstawione benzoazepiny jako modulatory receptora toll-podobnego
US20120220571A1 (en) 2009-08-26 2012-08-30 Wai John S Hiv integrase inhibitors
JP5624148B2 (ja) 2009-10-13 2014-11-12 エランコ・アニマル・ヘルス・アイルランド・リミテッド 大環状インテグラーゼ阻害剤
MX2012004706A (es) 2009-10-22 2012-06-08 Gilead Sciences Inc Derivados de purina o deazapurina utiles para el tratamiento de (inter alia) infecciones virales.
UA105556C2 (uk) 2010-01-27 2014-05-26 Віів Гелскер Компані Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
MX2012009869A (es) 2010-02-26 2012-09-12 Japan Tobacco Inc Derivado de 1, 3,4, 8-tetrahidro-2h-pirido[1, 2-a]pirazina y sus uso como inhibidor de la integrasa del vih.
RU2567385C2 (ru) 2010-04-02 2015-11-10 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Макроциклические ингибиторы интегразы
JP5766690B2 (ja) 2010-04-12 2015-08-19 塩野義製薬株式会社 インテグラーゼ阻害活性を有するピリドン誘導体
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
AP2013006706A0 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat AIDS
PH12013500015A1 (en) 2010-07-02 2013-02-18 Gilead Sciences Inc 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
PT2602260T (pt) 2010-08-05 2016-12-27 Shionogi & Co Processo para preparar composto possuindo atividade inibidora de integrase do vih
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
CN107970451A (zh) 2010-10-01 2018-05-01 帆德制药股份有限公司 Tlr激动剂和联合治疗的治疗应用
RU2016118628A (ru) 2010-10-01 2018-11-02 Вентиркс Фармасьютикалз, Инк. Способы лечения аллергических заболеваний
CA2814703A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
US8835411B2 (en) 2010-12-10 2014-09-16 Bristol-Myers Squibb Company HIV integrase inhibitors
CA2824779C (en) 2011-01-12 2020-01-14 Array Biopharma, Inc. Substituted benzoazepines as toll-like receptor modulators
ES2620605T3 (es) 2011-01-12 2017-06-29 Ventirx Pharmaceuticals, Inc. Benzoazepinas sustituidas como moduladores de receptores tipo Toll
KR101946499B1 (ko) 2011-04-08 2019-02-11 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 치료를 위한 피리미딘 유도체
UA111841C2 (uk) 2011-04-21 2016-06-24 Гіліад Сайєнсіз, Інк. Сполуки бензотіазолу та їх фармацевтичне застосування
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
CN116948019A (zh) 2011-05-17 2023-10-27 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法
SG194852A1 (en) 2011-05-18 2013-12-30 Janssen R & D Ireland Quinazoline derivatives for the treatment of viral infections and further diseases
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9493549B2 (en) 2011-07-25 2016-11-15 The Rockefeller University Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
CN110343135A (zh) 2011-08-16 2019-10-18 吉利德科学公司 替诺福韦艾拉酚胺(tenofovir alafenamide)半反丁烯二酸盐
TWI613211B (zh) 2011-10-07 2018-02-01 基利科學股份有限公司 抗病毒核苷酸類似物的製備方法
CA2851218A1 (en) 2011-10-12 2013-04-18 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
AU2012347453B2 (en) 2011-12-08 2017-11-23 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
WO2013091096A1 (en) 2011-12-20 2013-06-27 Boehringer Ingelheim International Gmbh Condensed triclyclic compounds as inhibitors of hiv replication
KR101939710B1 (ko) 2011-12-21 2019-01-17 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
JP6283320B2 (ja) 2012-02-08 2018-02-21 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染の治療のためのピペリジノ−ピリミジン誘導体
EP2828294A1 (en) 2012-03-23 2015-01-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to hiv-1 and their use
US9096586B2 (en) 2012-04-20 2015-08-04 Gilead Sciences, Inc. Therapeutic compounds
WO2014008636A1 (en) 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
WO2014014933A1 (en) 2012-07-20 2014-01-23 Merck Sharp & Dohme Corp. Hiv treatment with amido-substituted pyrimidinone derivatives
MX369417B (es) 2012-08-10 2019-11-07 Janssen Sciences Ireland Uc Derivados de alquilpirimidina para el tratamiento de infecciones víricas y otras enfermedades.
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
EA035327B1 (ru) 2012-10-10 2020-05-28 Янссен Сайенсиз Айрлэнд Юси Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
EA035012B1 (ru) 2012-10-18 2020-04-17 Рокфеллер Юниверсити (Дзе) Нейтрализующие анти-вич-антитела широкого спектра действия
ES2655843T3 (es) 2012-11-16 2018-02-21 Janssen Sciences Ireland Uc Derivados 2-aminoquinazolínicos sustituidos heterocíclicos para el tratamiento de infecciones víricas
CN104955847A (zh) 2012-12-04 2015-09-30 马里兰州大学(巴尔的摩) HIV-1 Env结合抗体、融合蛋白及其使用方法
WO2014099586A1 (en) 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
CA2893843C (en) 2012-12-21 2018-09-04 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
HK1214817A1 (en) 2012-12-27 2016-08-05 Japan Tobacco Inc. Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as hiv integrase inhibitor
MY191389A (en) 2013-02-21 2022-06-22 Janssen Sciences Ireland Uc 2-aminopyrimidine derivatives for the treatment of viral infections
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
WO2014172188A2 (en) 2013-04-16 2014-10-23 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
PT2997033T (pt) 2013-05-17 2018-01-25 Merck Sharp & Dohme Compostos heterocíclicos tricíclicos fundidos como inibidores de vih integrase
WO2014200880A1 (en) 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
NO2865735T3 (es) 2013-07-12 2018-07-21
DK3019503T3 (da) 2013-07-12 2017-11-20 Gilead Sciences Inc Polycykliske-carbamoylpyridon-forbindelser og anvendelse deraf til behandling af hiv-infektioner
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
US20160244510A1 (en) 2013-09-27 2016-08-25 Duke University Human monoclonal antibodies
MX367057B (es) 2013-09-27 2019-08-02 Merck Sharp & Dohme Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih.
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
WO2015117008A2 (en) 2014-01-31 2015-08-06 The Rockefeller University Broadly neutralizing anti-hiv antibodies and epitope therefor
NO2717902T3 (es) * 2014-06-20 2018-06-23
WO2016014484A1 (en) 2014-07-21 2016-01-28 The Rockefeller University Combination of broadly neutralizing hiv antibodies and viral inducers
EP3757105B1 (en) 2014-08-22 2024-07-24 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
CA2958591A1 (en) 2014-08-27 2016-03-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2016090545A1 (en) 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrate inhibitors
EP3229804B1 (en) 2014-12-09 2020-05-06 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3237397B1 (en) 2014-12-24 2018-11-21 Gilead Sciences, Inc. Isoquinoline compounds for the treatment of hiv
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
ES2735087T3 (es) 2014-12-24 2019-12-16 Gilead Sciences Inc Compuestos de pirimidina fusionados para el tratamiento de VIH
WO2016149710A2 (en) 2015-03-19 2016-09-22 Duke University Hiv-1 neutralizing antibodies and uses thereof
SMT202000255T1 (it) 2015-03-20 2020-07-08 The United States Of America As Represented By The Secretary Department Of Health And Human Services Anticorpi neutralizzanti diretti contro gp120 e loro utilizzo
US10081647B2 (en) 2015-03-26 2018-09-25 Merck Sharp & Dohme Corp. Phosphate substituted quinolizine derivatives useful as HIV integrase inhibitors
TR201905009T4 (tr) 2015-04-02 2019-05-21 Gilead Sciences Inc Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
AU2016256911B2 (en) 2015-05-07 2022-03-31 Agenus Inc. Anti-OX40 antibodies and methods of use thereof
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
JP2018527366A (ja) 2015-09-15 2018-09-20 ギリアード サイエンシーズ， インコーポレイテッド ＨＩＶを処置するためのｔｏｌｌ様レセプターのモジュレーター
WO2017087257A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
EP3377065B1 (en) 2015-11-17 2022-05-18 Merck Sharp & Dohme Corp. Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors
CA3007022A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
WO2017096276A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-gitr antibodies and methods of use thereof
WO2017096221A1 (en) 2015-12-02 2017-06-08 The Rockefeller University Bispecific anti-hiv broadly neutralizing antibodies
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
EP3383914A4 (en) 2015-12-02 2019-10-30 Agenus Inc. ANTI-OX40 ANTIBODIES AND METHOD OF USE THEREOF
CA3006963A1 (en) 2015-12-03 2017-06-08 Ludwig Institute For Cancer Research Ltd. Anti-ox40 antibodies and methods of use thereof
WO2017106071A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
PL3390441T3 (pl) 2015-12-15 2022-01-10 Gilead Sciences, Inc. Przeciwciała neutralizujące ludzki wirus niedoboru odporności
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
CN107022027B (zh) 2016-02-02 2022-03-08 中国疾病预防控制中心性病艾滋病预防控制中心 Hiv-1广谱中和抗体及其用途
CN107033241B (zh) 2016-02-03 2022-03-08 中国疾病预防控制中心性病艾滋病预防控制中心 Hiv-1广谱中和抗体及其用途
ES3035041T3 (en) 2016-06-23 2025-08-27 Viiv Healthcare Co Compositions and methods for the delivery of therapeutics
TW202138365A (zh) 2016-08-19 2021-10-16 美商基利科學股份有限公司 治療性化合物
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
AU2017367714B2 (en) 2016-12-02 2020-11-12 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as HIV integrase inhibitors
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
WO2018140368A1 (en) 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
AR110922A1 (es) 2017-02-06 2019-05-15 Gilead Sciences Inc Compuestos inhibidores del vih
TWI728250B (zh) 2017-06-21 2021-05-21 美商基利科學股份有限公司 靶向hiv gp120及cd3之多特異性抗體
SG11202002032SA (en) 2017-09-22 2020-04-29 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
US11274102B2 (en) 2017-10-30 2022-03-15 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
US11413292B2 (en) 2018-02-15 2022-08-16 Merck, Sharp & Dohme LLC Tricyclic heterocycle compounds useful as HIV integrase inhibitors
CA3101180A1 (en) 2018-04-27 2019-10-31 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
US11453669B2 (en) 2018-05-31 2022-09-27 Shionogi & Co., Ltd. Polycyclic pyridone derivative
CN112204029B (zh) 2018-05-31 2024-03-01 豪夫迈·罗氏有限公司 治疗性化合物
CA3102063A1 (en) 2018-05-31 2019-12-05 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative
ES2989103T3 (es) 2018-06-05 2024-11-25 Merck Sharp & Dohme Llc Compuestos de heterociclo tricíclico útiles como inhibidores de la integrasa del VIH
WO2019244066A2 (en) 2018-06-19 2019-12-26 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2020003093A1 (en) 2018-06-25 2020-01-02 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
JP7307412B2 (ja) 2018-06-27 2023-07-12 国立大学法人北海道大学 多環性カルバモイルピリドン誘導体を含有するアレナウイルス増殖阻害剤
HUE071524T2 (hu) 2018-07-03 2025-09-28 Gilead Sciences Inc HIV GP120-at célzó antitestek és alkalmazási eljárások
TWI829205B (zh) 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
EP4234560A3 (en) 2018-10-22 2023-09-13 Board of Regents of the University of Nebraska Antiviral prodrugs and nanoformulations thereof
CN113382737B (zh) 2018-11-29 2025-06-03 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
IL286328B1 (en) * 2019-03-22 2026-04-01 Gilead Sciences Inc Tricyclic bridging compounds of carbamoylpyridone and their pharmaceutical use
WO2020221294A1 (zh) 2019-04-30 2020-11-05 上海拓界生物医药科技有限公司 桥环-3,4-二氢-吡啶并[1,2-a]吡嗪-1,8-二酮化合物及其药物用途
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
TW202120510A (zh) 2019-11-13 2021-06-01 大陸商上海拓界生物醫藥科技有限公司 新型四環雜環化合物及其藥物用途
EP4066839A4 (en) 2019-11-28 2023-12-27 Shionogi & Co., Ltd PROPHYLACTIC AND THERAPEUTIC MEDICINAL PRODUCT FOR HIV INFECTIOUS DISEASES, CHARACTERIZED BY CONTAINING THE COMBINATION OF INTEGRAS INHIBITORS AND ANTI-HIV AGENTS
US12577241B2 (en) 2019-11-28 2026-03-17 Shionogi & Co., Ltd. Polycyclic pyridopyrazine derivative
CR20220418A (es) 2020-02-24 2022-10-10 Gilead Sciences Inc Compuestos tetracíclicos para el tratamiento de infecciones por vih
CA3192145A1 (en) 2020-09-30 2022-04-07 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202227445A (zh) 2020-10-30 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 抑制基因缺陷的ｈｉｖ病毒的用途
JP7591155B2 (ja) 2021-01-19 2024-11-27 ギリアード サイエンシーズ， インコーポレイテッド 置換ピリドトリアジン化合物及びその使用
WO2022177840A1 (en) 2021-02-16 2022-08-25 Merck Sharp & Dohme Llc Tetracyclic heterocycle compounds useful as hiv integrase inhibitors

Also Published As

Publication number Publication date
DOP2024000195A (es) 2025-03-31
US20250115620A1 (en) 2025-04-10
HUE067768T2 (hu) 2024-11-28
EP4438123A2 (en) 2024-10-02
HUE067983T2 (hu) 2024-12-28
ZA202406990B (en) 2025-04-30
DK4310087T3 (da) 2024-07-15
TWI856796B (zh) 2024-09-21
MX2024011695A (es) 2024-11-08
PE20252272A1 (es) 2025-09-15
JP7668430B1 (ja) 2025-04-24
DOP2026000092A (es) 2026-04-30
US20230339972A1 (en) 2023-10-26
US12054496B2 (en) 2024-08-06
JP2025081461A (ja) 2025-05-27
PT4305034T (pt) 2024-06-25
CN120081853A (zh) 2025-06-03
AU2025201145A1 (en) 2025-03-06
US20230339971A1 (en) 2023-10-26
AU2025205450A1 (en) 2025-07-31
KR20260049880A (ko) 2026-04-14
ZA202501263B (en) 2025-10-29
NZ818531A (en) 2025-06-27
PL4305034T3 (pl) 2024-10-14
FI4305034T3 (fi) 2024-07-25
EP4438123A3 (en) 2024-12-04
TW202446773A (zh) 2024-12-01
LT4310087T (lt) 2024-08-26
CL2024002988A1 (es) 2025-02-21
AU2023249631B2 (en) 2025-04-24
EP4310087B1 (en) 2024-07-03
WO2023196875A1 (en) 2023-10-12
SI4310087T1 (sl) 2024-09-30
PT4310087T (pt) 2024-08-02
CO2024013492A2 (es) 2024-10-31
ES2992835T3 (en) 2024-12-18
DK4305034T3 (da) 2024-07-01
JP2025071130A (ja) 2025-05-02
HRP20241051T1 (hr) 2024-11-08
SI4305034T1 (sl) 2024-08-30
LT4305034T (lt) 2024-07-10
CA3245817A1 (en) 2023-10-12
CR20240405A (es) 2024-11-28
JP7668428B2 (ja) 2025-04-24
ES2988416T3 (es) 2024-11-20
AU2025201145B2 (en) 2025-03-13
PE20250151A1 (es) 2025-01-16
CN120081853B (zh) 2026-04-24
AU2023249631A1 (en) 2024-10-03
TWI843506B (zh) 2024-05-21
TW202400172A (zh) 2024-01-01
EP4310087A1 (en) 2024-01-24
EP4305034A1 (en) 2024-01-17
NZ814609A (en) 2025-05-02
JP2025510905A (ja) 2025-04-15
TW202400165A (zh) 2024-01-01
FI4310087T3 (fi) 2024-08-09
PL4310087T3 (pl) 2024-11-04
US12024528B2 (en) 2024-07-02
HRP20240986T1 (hr) 2024-11-08
CN118922419B (zh) 2025-11-28
PE20252269A1 (es) 2025-09-15
DOP2026000091A (es) 2026-04-30
CL2025002302A1 (es) 2025-11-21
KR20250002321A (ko) 2025-01-07
EP4305034B1 (en) 2024-06-12
CN118922419A (zh) 2024-11-08
IL315684A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
DOP2026000092A (es) Compuestos de carbamoilpiridona tricíclicos en puente y usos de estos
CL2024001793A1 (es) Compuestos de piridotriazina sustituidos y usos de estos
CR20220418A (es) Compuestos tetracíclicos para el tratamiento de infecciones por vih
MX2021011394A (es) Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico.
DOP2026000100A (es) Compuestos de carbamoilpiridona tricíclicos en puente y usos de estos
PA8547501A1 (es) Inhibidores de la proteasa del vih, composiciones que los contienen, sus usos farmaceuticos y materiales para su sintesis
CO2022016899A2 (es) Moduladores de il-17a
CO2022018636A2 (es) Moduladores de il-17a
CL2024001565A1 (es) Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa, composición que los comprende y su uso.
BRPI0513858B8 (pt) compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende
CL2023000772A1 (es) Compuestos heterocíclicos de heteroarilo y usos de los mismos
CL2023002274A1 (es) Compuestos tricíclicos y usos de los mismos
DOP2026000103A (es) Compuestos de carbamoilpiridona tricíclicos en puente y usos de estos
AR134104A1 (es) Compuestos de carbamoilpiridona tricíclicos en puente y usos de estos
AR134105A1 (es) Compuestos de carbamoilpiridona tricíclicos en puente y usos de estos
AR129007A1 (es) Compuestos de carbamoilpiridona tricíclicos con puente y usos de estos
CO2025003259A2 (es) Formulaciones que comprenden g-csf y usos de las mismas
CL2025002072A1 (es) Inhibidores de prmt5–mta.
AR131437A1 (es) Compuestos inhibidores de pkmyt1
ECSP034892A (es) Inhibidores de proteasa vih, composiciones que los contienen, sus usos farmaceuticos y materiales para su síntesis
SV2004001553A (es) Proteasa inhibidora de vih, composiciones que las contienen, sus usos farmaceuticos y materiales para su sintesis
UY27331A1 (es) Inhibidores de la proteasa del vih, composiciones que los contienen, sus usos farmacéuticos y materiales para su síntesis
UY27330A1 (es) Inhibidores de la proteasa del vih, composiciones que los contienen, sus usos farmacéuticos y materiales para su síntesis.